Clinical trials: CKD
Chronic Kidney Disease
A Study to Evaluate the Safety and Pharmacokinetics With MEDI8367 Administered in Healthy Subjects, and in Subjects With Chronic Kidney Disease
This Phase I First in Human (FIH) study is being conducted to determine the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity profile of MEDI8367 across the dose range.
- Trial name
- NCT04365218
- Testing
- MEDI8367
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants, Alzheimer Disease
A Phase 1 Study to Assess the Safety and Effects of Single and Multiple Doses of KS101 in Healthy Volunteers
This study is the first clinical trial involving study drug KS101. The goal of this clinical trial is to investigate whether KS101 is safe, whether it causes side effects, and how KS101 is broken down in the body, in healthy…
- Conditions
- Healthy Participants, Alzheimer Disease, Chronic Kidney Disease
- Trial name
- NCT07143331
- Testing
- Part 1 KS101, Part 2 with Food, Part 2 without food
- Where
- Australia
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Klotho Sciences Australia Pty Ltd.
Healthy Subjects, Pharmacokinetics of ASP8232
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease
This study consists of two parts. Part 1 evaluates the effect of renal impairment on the PK and PD of a single dose of ASP8232. In addition, the safety and tolerability will be assessed.
- Conditions
- Healthy Subjects, Pharmacokinetics of ASP8232, Pharmacodynamics of ASP8232, Chronic Kidney Disease (CKD)
- Trial name
- NCT02218099
- Testing
- ASP8232
- Where
- 3 sites in Bulgaria, Moldova and 1 more
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Chronic Kidney Disease
A Study to Learn About How a New Nurandociguat Tablet is Absorbed and Processed in the Body Compared to an Old Tablet and How Food Affects the Way the New Tablet is Absorbed and Processed in the Body
Researchers conduct this clinical study to learn more about a new tablet of a medicine called nurandociguat. Nurandociguat is being developed as a possible treatment for people with chronic kidney disease (CKD) which is a…
- Trial name
- NCT07722585
- Testing
- Nurandociguat (BAY3283142) old tablet - SD, Nurandociguat (BAY3283142) new tablet - SD, Nurandociguat (BAY3283142) old tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Type II Diabetes Mellitus
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects
This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects
- Trial name
- CKD-371 (NCT05544214)
- Testing
- CKD-371
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hemodialysis, Healthy
Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects
The objectives of this study are to evaluate the in vivo metabolite profiling and characterization of CR845 administered intravenously (IV) in patients on hemodialysis (HD) and in healthy subjects; and to determine the…
- Trial name
- NCT03947970
- Testing
- [14C] CR845
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cara Therapeutics, Inc.
Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD) or non-proliferative diabetes retinopathy (NPDR).
- Conditions
- Chronic Kidney Disease, Non-proliferative Diabetic Retinopathy, Healthy Volunteers
- Trial name
- NCT06487845
- Testing
- BAY3283142
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
Anemia, Chronic Kidney Disease
Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure, Cancer
- Trial name
- NCT00097747
- Testing
- peginesatide
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Affymax
Renal Impairment
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
The purpose of this study is to evaluate the drug levels of mezigdomide in participants with renal impairment.
- Trial name
- NCT06318676
- Testing
- Mezigdomide
- Where
- 3 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Celgene
Chronic Kidney Failure, Secondary Hyperparathyroidism
Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience
The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.
- Trial name
- PROTECT (NCT01083186)
- Where
- 24 sites in Greece
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Disease
Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance
The purpose of this study is to investigate the safety and tolerability of LY2623091 after multiple oral dosing in healthy men and women of non-childbearing potential.
- Trial name
- NCT01237899
- Testing
- LY2623091, Eplerenone
- Where
- Netherlands
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Renal Impairment, End-stage Kidney Disease
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of AZD4144 in Participants With Severe Renal Impairment, End-stage Kidney Disease, and in Healthy Participants
A study to investigate the pharmacokinetics, safety, and tolerability of AZD4144 in participants with severe renal impairment, end-stage kidney disease, and in healthy participants.
- Conditions
- Renal Impairment, End-stage Kidney Disease, Healthy Participants
- Trial name
- NCT06693765
- Testing
- AZD4144
- Where
- 2 sites in Bulgaria, Romania
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease
The purpose of this first-in-human (FIH) study is to evaluate safety, tolerability, pharmacokinetic (PK) of OJR520.
- Trial name
- NCT07235059
- Testing
- OJR520
- Where
- 2 sites in United States, Germany
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteer
Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects
To investigate the safety, tolerability, pharmacokinetics and effects of BAY1101042 in healthy male subjects after a single oral dose and multiple once daily dosing for 7 days
- Trial name
- NCT03252002
- Testing
- BAY1101042
- Where
- 2 sites in Germany
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Kidney Disease
Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers
This study will be a randomised, open-label, 3-period, 3-treatment, single-dose, crossover study in healthy subjects The study will be performed at a single study centre in the United Kingdom.
- Trial name
- NCT04734275
- Testing
- AZD5718
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Anemia of Chronic Kidney Disease
Project Aura: Co-design of a Home-based Monitoring Service
Co-design of a home-based haemoglobin monitoring system with participants with anaemia of chronic kidney disease.
- Trial name
- NCT04112615
- Testing
- Blood measurement
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Entia Ltd
Chronic Kidney Disease
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
This is a randomized, placebo controlled, double-blind study with two separate cohorts to assess safety, tolerability and pharmacokinetics of verinurad and allopurinol in healthy subjects.
- Trial name
- NCT03836599
- Testing
- Verinurad, Allopurinol
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Kidney Disease(CKD)
Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects
The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects
- Trial name
- NCT06344936
- Testing
- HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Chronic Kidney Disease
A Study in Healthy Subjects to Assess Drug Availability of 4 Different Formulations of Verinurad and Allopurinol
This study is a single centre, randomised, open-label, single-dose, 5-period, 5-treatment, crossover study in healthy male and female subjects.
- Trial name
- NCT04550234
- Testing
- Verinurad prolonged release HPMC capsule, Allopurinol Tablet, Verinurad/Allopurinol FDC Capsule
- Where
- Germany
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram